Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the sales growth in the first three months of 2024, driven by increased demand for our GLP-1-based diabetes and obesity treatments. More patients benefit from our innovative treatments, and the agreement to acquire the three Catalent manufacturing sites will enable us to serve significantly more people living with diabetes and obesity in the future. Within R&D, we are pleased with the positive results from the kidney outcomes trial with semaglutide and the label expansion for cardiovascular risk reduction for Wegovy® in the US." On 2 May 2024 at 13.00 CEST, corresponding to 07.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.

Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER). Sales within Diabetes and Obesity care increased by 25% in Danish kroner to DKK 61.0 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 30% in Danish kroner (32% at CER) and Obesity care growing by 41% in Danish kroner to DKK 11.0 billion (42% at CER). Rare disease sales decreased by 4% measured in Danish kroner (3% at CER). In the first quarter of 2024, Novo Nordisk successfully completed the FLOW kidney outcomes trial with semaglutide 1.0 mg. Further, Wegovy® was approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease, and Awiqli®, once-weekly insulin icodec, was recommended for EU approval. In February 2024, Novo Nordisk announced an agreement to acquire three fill-finish sites from Novo Holdings A/S in connection with a transaction where Novo Holdings A/S has agreed to acquire Catalent, Inc. Novo Nordisk expects that the acquisition will be completed towards the end of 2024. For the 2024 outlook, sales growth is now expected to be 19-27% at CER, and operating profit growth is now expected to be 22-30% at CER. Growth reported in Danish kroner is now expected to be in line with CER growth for both sales and operating profit.

Klingt gut

Novo-Nordisk erzielt im 1. Quartal einen Umsatz von DKK 65,34 Mrd (VJ: DKK 53,36 Mrd), ein EBIT von DKK 31,85 Mrd (VJ: DKK DKK 25,00 Mrd, Analystenprognose: DKK 29,04 Mrd) und einen Nettogewinn von DKK 25,40 Mrd (VJ: DKK 19,81 Mrd). Im Ausblick auf 2024 sieht das Unternehmen ein bereinigtes Umsatzplus von 19% bis 27% (Prognose: 25,9%) und einen Anstieg beim operativen Gewinn von 22% bis 30% (Prognose: 28,6%).

Die Zahlen werden hoffentlich richtig gut wieder 🏆

Zahlen morgen 7:30 Uhr … bin gespannt

… bin sehr gespannt auf den Donnerstag 😌 Kann mir kaum vorstellen, dass Novo da nicht mitgezogen ist.

… ohne Worte https://amp.focus.de/finanzen/boerse/aktienkurs-macht-satz-nach-oben-experten-neues-abnehmmittel-von-eli-lilly-wird-bestverkaufte-arznei-der-welt_id_259902581.html

… keine Ahnung, was du unter Volldampf verstehst.

Und doch wieder seitwärts

… so ein feiner stabiler Jahreschart hier 😌

Von Dominic Chopping KOPENHAGEN (Dow Jones) - Novo Nordisk verstärkt sich mit einem Zukauf im Bereich der Therapie von Herz-Kreislauferkrankungen. Wie der dänische Pharmakonzern mitteilte, erwirbt er für bis zu 1,03 Milliarden Euro das deutsche Biotechnologieunternehmen Cardior Pharmaceuticals GmbH mit Sitz in Hannover. Damit will Novo Nordisk in Bereiche außerhalb seines Kernmarkts für Diabetes-Therapie und Gewichtsreduktion expandieren.

du sprichst mir aus der Seele 😀

i like ... ❤️ 🚀

So ist es! Volldampf nach oben dank Lilly

Yes!